Update on the Use of SSRIs and SNRIs with Children and Adolescents in Clinical Practice
- PMID: 27047551
- PMCID: PMC4791100
Update on the Use of SSRIs and SNRIs with Children and Adolescents in Clinical Practice
References
-
- Atkinson SD, Prakash A, Zhang Q, Pangallo BA, Bangs ME, Emslie GJ, March JS. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. Journal of Child and Adolescent Psychopharmacology. 2014;24(4):180–189. doi: 10.1089/cap.2013.0146. - DOI - PubMed
-
- Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller, Zelazny J. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. Journal of the American Medical Association. 2008;299(8):901–913. doi: 10.1001/jama.299.8.901. - DOI - PMC - PubMed
-
- Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. Journal of the American Medical Association. 2007;297(15):1683–1696. - PubMed
-
- Canadian Agency for Drugs and Technology in Health (CADTH) Rapid Response Report: Summary with Critical Appraisal. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015. Second Generation Antidepressants for Pediatric Patients with Major Depressive Disorder and Anxiety Disorder: A Review of the Clinical Effectiveness and Safety. Retrieved from https://www.cadth.ca/second-generation-antidepressants-pediatric-patient.... - PubMed
LinkOut - more resources
Full Text Sources